1. The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies
- Author
-
Yu-Shun Qiao, Yin-He Chai, Hong-Jian Gong, Zhiyessova Zhuldyz, Coen D. A. Stehouwer, Jian-Bo Zhou, Rafael Simó, Institut Català de la Salut, [Qiao YS, Chai YH, Gong HJ, Zhuldyz Z] Beijing Tongren Hospital, Capital Medical University, Beijing, China. [Stehouwer CDA] Department of Internal Medicine and Cardiovascular Research Institute Maastricht (CARIM) School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, Netherlands. [Zhou JB] Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. [Simó R] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
NATIONAL-HEALTH ,Atròfia muscular - Factors de risc ,Sarcopenia ,enfermedades del sistema nervioso::manifestaciones neurológicas::manifestaciones neuromusculares::atrofia muscular::sarcopenia [ENFERMEDADES] ,HbA1c ,Nervous System Diseases::Neurologic Manifestations::Neuromuscular Manifestations::Muscular Atrophy::Sarcopenia [DISEASES] ,Endocrinology, Diabetes and Metabolism ,enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus [ENFERMEDADES] ,NUTRITION EXAMINATION SURVEY ,prediabetes ,DIAGNOSIS ,técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,DISEASE ,Diseases of the endocrine glands. Clinical endocrinology ,Diabetic complications ,sarcopenia ,Endocrinology ,Diabetes mellitus ,Risk Factors ,Observational study ,STRENGTH ,diabetic complications ,Humans ,MUSCLE MASS ,BODY ,OLDER-ADULTS ,Glycated Hemoglobin ,Diabetis - Complicacions ,INSULIN-RESISTANCE ,RC648-665 ,Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus [DISEASES] ,Observational Studies as Topic ,OBESITY ,diabetes mellitus ,observational study ,Systematic Review ,Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Prediabetes ,human activities - Abstract
Diabetic complications; Prediabetes; Sarcopenia Complicaciones de la diabetes; Prediabetes; Sarcopenia Complicacions de la diabetis; Prediabetis; Sarcopènia Aim: We performed a meta-analysis of observational studies to evaluate the association between the presence of sarcopenia and HbA1c, prediabetes, diabetes and diabetic complications. Method: The PubMed, Embase, Cochrane and Web of Science databases were searched from inception to May 2021. We included full-text English language articles that reported the prevalence of sarcopenia in patients with and without diabetes. Quality assessment was performed according to the Newcastle- Ottawa scale for observational studies. Results: Sixteen studies were included in the meta-analysis. Three studies showed that high HbA1c levels lead to loss of muscle mass, and one study involving prediabetes showed that people with prediabetes had lower muscle mass, strength, and performance than non-diabetic population. Seven studies showed that people with diabetes had a higher risk of sarcopenia than those without diabetes (combined OR: 2.09, 95% CI:1.62-2.70). The remaining five studies suggested that diabetic complications increased the risk of sarcopenia (combined OR: 2.09,95% CI:1.62-2.70). Conclusion: High HbA1c levels, prediabetes, diabetes and diabetes complications were associated with an increased risk of sarcopenia. Therapeutic strategies addressed to avoid the conversion of IGT to diabetes and to optimize glycemic control are warranted to prevent or arrest sarcopenia in the diabetic population This work was supported by the National Natural Science Foundation of China (No. 82070851, 81870556), Beijing Municipal Administration of Hospitals’ Youth Program (QML20170204), Excellent Talents in Dongcheng District of Beijing.
- Published
- 2021